一名化脓性汗腺炎患者使用司库奇尤单抗后出现迟发性药物过敏反应。
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.
机构信息
Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.
Dermatology, Henry Ford Hospital, Detroit, Michigan, USA
出版信息
BMJ Case Rep. 2022 May 17;15(5):e249684. doi: 10.1136/bcr-2022-249684.
Abstract
A woman in her 30s presented to the dermatology clinic with widespread, pruritic, red papules and plaques involving the ears, trunk and extremities. The rash developed a few days after receiving her second injection of secukinumab, which was initiated for recalcitrant Hurley stage III hidradenitis suppurativa. Investigations revealed a psoriasiform drug hypersensitivity reaction secondary to secukinumab. In this report, we describe the clinical course, histopathological correlation and treatment of this rarely documented reaction.
摘要
一位 30 多岁的女性因广泛分布的瘙痒性红色丘疹和斑块就诊于皮肤科诊所，累及耳朵、躯干和四肢。皮疹在接受第二剂司库奇尤单抗治疗后几天出现，该治疗用于治疗难治性 Hurley III 级化脓性汗腺炎。检查显示司库奇尤单抗引起的银屑病样药物超敏反应。在本报告中，我们描述了这种罕见报道的反应的临床经过、组织病理学相关性和治疗。
相似文献
1
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.一名化脓性汗腺炎患者使用司库奇尤单抗后出现迟发性药物过敏反应。
BMJ Case Rep. 2022 May 17;15(5):e249684. doi: 10.1136/bcr-2022-249684.
2
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.一名化脓性汗腺炎患者对司库奇尤单抗的迟发性药物超敏反应。
Drug Ther Bull. 2024 Apr 25;62(5):77-79. doi: 10.1136/dtb.2023.249684rep.
3
Secukinumab in the treatment of hidradenitis suppurativa.司库奇尤单抗治疗化脓性汗腺炎。
Immunotherapy. 2023 Dec;15(17):1449-1457. doi: 10.2217/imt-2023-0103. Epub 2023 Oct 16.
4
Secukinumab-induced paradoxical hidradenitis suppurativa.司库奇尤单抗诱导的化脓性汗腺炎。
Dermatol Ther. 2020 Jan;33(1):e13150. doi: 10.1111/dth.13150. Epub 2019 Nov 12.
5
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
6
Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.病例报告：采用不同治疗方法治疗化脓性汗腺炎和银屑病共存。
F1000Res. 2019 Nov 26;8:2002. doi: 10.12688/f1000research.21216.2. eCollection 2019.
7
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.与赫尔利分期相比，国际化脓性汗腺炎严重程度评分系统（IHS4）作为化脓性汗腺炎疾病严重程度的整体衡量指标：司库奇尤单抗的SUNRISE和SUNSHINE 3期试验的事后分析
J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499. doi: 10.1111/jdv.19681. Epub 2023 Dec 6.
8
Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.化脓性汗腺炎抗TNF治疗期间银屑病发病：司库奇尤单抗成功缓解两种病症。
Skinmed. 2023 Mar 29;21(1):57-58. eCollection 2023.
9
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.古塞库单抗治疗化脓性汗腺炎、银屑病和克罗恩病。
J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.
10
Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.司库奇尤单抗可能是治疗化脓性汗腺炎继发系统性淀粉样变的方法。
Dermatol Ther. 2020 Nov;33(6):e14205. doi: 10.1111/dth.14205. Epub 2020 Sep 11.
引用本文的文献
1
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
本文引用的文献
1
Delayed-type hypersensitivity to secukinumab with tolerance to ixekizumab.对司库奇尤单抗的迟发型超敏反应伴对依奇珠单抗的耐受性。
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3626-3628. doi: 10.1016/j.jaip.2020.06.016. Epub 2020 Jun 22.
2
Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events.生物制剂的超敏反应（第一部分）：在复杂的免疫源性不良事件中，过敏作为一项重要的鉴别诊断。
Allergo J Int. 2020;29(4):97-125. doi: 10.1007/s40629-020-00126-6. Epub 2020 May 12.
3
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.司库奇尤单抗治疗中度至重度化脓性汗腺炎：一项开放标签试验的结果
J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7.
4
Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions.司库奇尤单抗诱导的迟发型药物超敏反应。
J Clin Rheumatol. 2020 Sep;26(6):e197-e198. doi: 10.1097/RHU.0000000000001065.
5
Secukinumab-induced paradoxical pustular psoriasis.司库奇尤单抗诱发的反常脓疱型银屑病。
Clin Exp Dermatol. 2019 Jan;44(1):72-73. doi: 10.1111/ced.13731. Epub 2018 Aug 20.
6
Secukinumab-Induced Psoriasiform Eruption.司库奇尤单抗诱导的银屑病样皮疹。
JAMA Dermatol. 2017 Nov 1;153(11):1194-1195. doi: 10.1001/jamadermatol.2017.2826.
7
Adverse skin reaction to Secukinumab.司库奇尤单抗引起的皮肤不良反应。
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e432-e433. doi: 10.1111/jdv.14248. Epub 2017 Jul 3.
8
Drug eruption caused by secukinumab.司库奇尤单抗引起的药物疹。
Eur J Dermatol. 2017 Feb 1;27(1):67-68. doi: 10.1684/ejd.2016.2900.
9
Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.司库奇尤单抗是一种新型抗白细胞介素-17A抗体，在人体体外试验中显示出较低的免疫原性潜力，与其他具有低临床免疫原性的已上市生物疗法相当。
MAbs. 2016;8(3):536-50. doi: 10.1080/19420862.2015.1136761. Epub 2016 Jan 28.
Zotero 插件